789 related articles for article (PubMed ID: 27813361)
1. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
[TBL] [Abstract][Full Text] [Related]
2. Low serum dehydroepiandrosterone examined by liquid chromatography-tandem mass spectrometry correlates with poor prognosis in hormone-naïve prostate cancer.
Miyoshi Y; Uemura H; Umemoto S; Sakamaki K; Taguri M; Suzuki K; Shibata Y; Masumori N; Ichikawa T; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Harada M; Kubota Y
Prostate; 2016 Mar; 76(4):376-82. PubMed ID: 26616365
[TBL] [Abstract][Full Text] [Related]
3. High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients.
Miyoshi Y; Uemura H; Umemoto S; Sakamaki K; Morita S; Suzuki K; Shibata Y; Masumori N; Ichikawa T; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Harada M; Kubota Y
BMC Cancer; 2014 Sep; 14():717. PubMed ID: 25256077
[TBL] [Abstract][Full Text] [Related]
4. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
5. Does baseline total testosterone improve the yielding of prostate cancer screening?
Botelho F; Pina F; Figueiredo L; Cruz F; Lunet N
Eur J Cancer; 2012 Jul; 48(11):1657-63. PubMed ID: 22342552
[TBL] [Abstract][Full Text] [Related]
6. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
7. Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml.
Shiota M; Takeuchi A; Sugimoto M; Dejima T; Kashiwagi E; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Nov; 35(11):6137-45. PubMed ID: 26504040
[TBL] [Abstract][Full Text] [Related]
8. Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Suzuki K; Takahashi K
J Urol; 2006 Oct; 176(4 Pt 1):1387-91. PubMed ID: 16952639
[TBL] [Abstract][Full Text] [Related]
9. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
Partin AW; Carter HB; Chan DW; Epstein JI; Oesterling JE; Rock RC; Weber JP; Walsh PC
J Urol; 1990 Apr; 143(4):747-52. PubMed ID: 1690309
[TBL] [Abstract][Full Text] [Related]
10. Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.
Pejčić T; Tosti T; Tešić Ž; Milković B; Dragičević D; Kozomara M; Čekerevac M; Džamić Z
Prostate; 2017 Jul; 77(10):1082-1092. PubMed ID: 28594074
[TBL] [Abstract][Full Text] [Related]
11. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM
J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967
[TBL] [Abstract][Full Text] [Related]
12. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
Yesner R; Kelly LJ; Chan YK
Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
[TBL] [Abstract][Full Text] [Related]
13. A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL.
Miyoshi Y; Kawahara T; Uemura H
BMC Cancer; 2022 Nov; 22(1):1169. PubMed ID: 36371158
[TBL] [Abstract][Full Text] [Related]
14. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
15. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness and predictive value of PSA density, adjusted by transition zone volume, in men with PSA levels between 2 and 4 ng/ml].
Janane A; Hajji F; Ismail T; Jawad C; Elondo JC; Dakka Y; Ghadouane M; Ameur A; Abbar M; Albouzidi A
Actas Urol Esp; 2012 Feb; 36(2):93-8. PubMed ID: 22188752
[TBL] [Abstract][Full Text] [Related]
17. Histopathologic characterization of prostate diseases in Madinah, Saudi Arabia.
Albasri A; El-Siddig A; Hussainy A; Mahrous M; Alhosaini AA; Alhujaily A
Asian Pac J Cancer Prev; 2014; 15(10):4175-9. PubMed ID: 24935366
[TBL] [Abstract][Full Text] [Related]
18. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
Kjaer TN; Ornstrup MJ; Poulsen MM; Jørgensen JO; Hougaard DM; Cohen AS; Neghabat S; Richelsen B; Pedersen SB
Prostate; 2015 Sep; 75(12):1255-63. PubMed ID: 25939591
[TBL] [Abstract][Full Text] [Related]
20. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
